Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | ACP3 | P15309 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | PTPRC | P08575 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917013 | 1.00 | TSHR (0.61) | TSHRLMNAALDH1A1ALOX15CA12 | |
| Fluoride SCHEMBL11418765 | 0.98 | TSHR (0.59) | TSHRLMNAALDH1A1ALOX15CA12 | |
| SCHEMBL15158344 | 0.90 | TSHR (0.59) | TSHRLMNAALDH1A1ALOX15CA12 | |
| SCHEMBL8408187 | 0.86 | TSHR (0.64) | TSHRLMNAALDH1A1ALOX15CA12 | |
| SCHEMBL30764114 | 0.86 | TSHR (0.64) | TSHRLMNAALDH1A1ALOX15CA12 | |
| Phenylphosphonic Acid SCHEMBL28269525 | 0.84 | ALDH1A1 (0.64) | TSHRLMNAALDH1A1ALOX15CA12 | |
| SCHEMBL16146800 | 0.83 | TSHR (0.50) | TSHRLMNAALDH1A1ALOX15CA12 | |
| SCHEMBL3397329 | 0.82 | TSHR (0.59) | TSHRLMNAALDH1A1ALOX15CA12 | |
| SCHEMBL11418761 | 0.82 | TSHR (0.59) | TSHRLMNAALDH1A1ALOX15CA12 | |
| SCHEMBL18263894 | 0.82 | TSHR (0.59) | TSHRLMNAALDH1A1ALOX15CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438056-B1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS LLC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9174932-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9000208-B2 | Glutamate derivatives or salts thereof | AJINOMOTO CO., INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8877739-B2 | Prophylactic agent or therapeutic agent for diabetes or obesity | AJINOMOTO CO., INC. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20140303122-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | AJINOMOTO CO., INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2554165-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | Ajinomoto Co., Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| EP-2551262-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | Ajinomoto Co., Inc. (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | AJINOMOTO CO., INC. (JP) | 2013-01-17 | — | — | US | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | CASR, GIPR, GRPR | TSHR 233/4885LMNA 4842/4885ALDH1A1 2603/4885 |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | TSHR 4171/4885LMNA 4131/4885ALDH1A1 1117/4885 |
| US-20140303122-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | TSHR 481/4885LMNA 3955/4885ALDH1A1 2705/4885 |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | GPR119, GIPR, CASR | TSHR 266/4885LMNA 2493/4885ALDH1A1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.